Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
Returns on capital
Vicore Pharma Holding AB management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-43.6%
avg -8.7%
ROIC
-41.3%
avg -8.3%
ROA
-39.2%
avg -7.8%
Analysis
ROA is currently the strongest return metric at -39.2% versus its period average of -7.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ahmed S. Mousa | Chief Executive Officer | SEK 8.38M | 42 | — | — |
Hans Jeppsson | Chief Financial Officer | — | — | — | — |
Jason Hoffman | VP & Head of Human Resources | — | — | — | — |
Jimmie Hofman | Chief Business Officer | — | — | — | — |
Karam Hijji | General Counsel | — | — | — | — |
Mikael Nygård | Chief Operating Officer | — | — | — | — |
Helen Barker | Chief Technology Officer | — | — | — | — |
Johanna Grans | Head of Non-Clinical Development | — | — | — | — |
Lene Eskildsen | Head of Quality Assurance | — | — | — | — |
Megan Richards | VP of Investor Relations, Communications & Portfolio Strategy | — | — | — | — |
Nina Carlen | Chief Administrative Officer | — | — | — | — |
Bernt van den Blink | Chief Medical Officer | — | — | — | — |
Rob Slack | Chief Scientific Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 24, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -34.8% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at -34.8% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Vicore Pharma Holding AB compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about VCRE's management, answered from reported figures.
Who manages VCRE?
Vicore Pharma Holding AB (VCRE) lists 13 active executives. The top listed executive is Ahmed S. Mousa, Chief Executive Officer.
Continue the stock analysis
Jump to another research area for this company.